Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers

REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS) stable solid cancers.

The multi-cohort design will allow for the examination of 8 separate cohorts of different cancers to determine whether further examination may be warranted in the individual indications.

Study Overview

• Status: Withdrawn
• Conditions: Soft Tissue Sarcoma; Small Cell Lung Carcinoma; Colorectal Neoplasms; Anal Squamous Cell Carcinoma; Malignant Pleural Mesothelioma; Castrate Resistant Prostate Cancer; Gastroenteropancreatic Neuroendocrine Neoplasm; Neuroendocrine Carcinoma of Prostate
• Intervention / Treatment: Combination product: Regorafenib in combination with Tislelizumab

Detailed Description

This is a non-randomized, multicenter, open-label, multi-cohort, phase II trial to evaluate the efficacy and safety of Rego-Tisle in adult patients with solid tumors that are advanced, pretreated and refractory to standard therapy. Approximately 322 evaluable patients (between 15 and 82 per cohort) in around 65 sites will be enrolled to power the trial efficiently to measure the primary endpoint, Progression Free Survival at 6 months (PFS-6).

Patients should have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST 1.1), an Eastern Cooperative Oncology Group Performance Scale (ECOG PS) 0-1, and adequate organ function.

The trial will include patients who had been diagnosed with a histologically or cytologically confirmed solid tumor belonging to any of the types in the cohorts to be enrolled. To be eligible, patient must meet the criteria for tumor type, stage and prior anti-cancer therapy according to inclusion criteria.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed and dated PICF obtained prior to any trial-specific procedure that is not part of standard patient care.
2. Patient is ≥ 18 years-old at the time of PICF signature (or the legal age of consent in the jurisdiction in which the trial is taking place).
3. Histologically or cytologically confirmed solid tumor belonging to one of the cohorts specified in the protocol. To be eligible, patient must meet the criteria for tumor type, stage and prior anti-cancer therapy according to the protocol.

4. Tumor must be:

   • In all colorectal (CRC patients) and in any non-CRC patient with dMMR/MSI testing available prior to enrollment: pMMR/MSS tumor based on IHC, MSI-PCR or NGS testing, as performed at the site prior to enrollment according to site's standard practice.
   • In any non-CRC patient with unknown dMMR/MSI status: the site must confirm at screening that the patient has available and retrievable archival tumor tissue from the primary or metastatic site, for submission to a central laboratory for dMMR/MSI testing.
5. Measurable disease by CT or MRI per Response Evaluation Criteria in Solid Tumors (version 1.1), based on tumor assessment performed within 28 days of enrollment.
6. Progressive cancer at the time of trial entry based on clinical or radiographic findings or tumor marker evaluation, according to Investigator's judgment, or cancer that is not amenable to standard therapies even if not progressing.
7. ECOG Performance Scale score of 0 or 1 at enrollment.
8. Adequate hematologic and organ function as assessed by the following laboratory tests, performed at screening (specified within the protocol).
9. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
10. Women of childbearing potential (CBP) must have confirmed negative serum pregnancy test (for β-hCG) within 7 days prior to enrollment.
11. Women of CBP must agree to remain completely abstinent (complete avoidance of heterosexual intercourse) or use highly effective contraceptive methods (i.e., with a failure rate of < 1% per year) during the Treatment Phase and for at least 7 months after the last trial treatment intervention.
12. Men who are sexually active with women of CBP must agree to remain completely abstinent (complete avoidance of heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm during the Treatment Phase and for a total of 7 months post-treatment completion.

Exclusion Criteria:

1. Prior treatment with regorafenib.

2. Prior treatment with a PD1, PD-L1/PD-L2, or CTLA-4 inhibitor, or any other drug or antibody targeting T-cell co-stimulation or checkpoint pathways, except in patients that meet all the following criteria:

   • Patient received a PD1, PD-L1/PD-L2, or CTLA-4 inhibitor, or any other drug or antibody targeting T-cell co-stimulation or checkpoint pathways in either:

     1. Neoadjuvant and/or adjuvant setting and had no relapse within 12 months of completing immunotherapy
     2. Advanced disease setting and had no progression during immunotherapy
   • Patient tolerated immunotherapy and did not need to discontinue treatment due to intolerable toxicity

3. Evidence of progressive or symptomatic CNS metastases. Patients with treated CNS metastases are eligible if they meet all the following criteria:

   • Minimal neurologic symptoms
   • Evidence of stable disease (for at least 2 weeks prior to enrollment) or response on a follow-up scan performed after CNS treatment completion
   • Require corticosteroids at a dose ≤ 10 mg daily of prednisone or equivalent
4. Previous treatment with live vaccine within 28 days of planned start of trial drugs (seasonal flu vaccines that do not contain a live virus are permitted).
5. Concurrent participation in another clinical study, unless it is: (a) an observational (noninterventional) study, or (b) the follow-up period of an interventional trial and patient did not receive an investigational agent/device within 28 days before enrollment (or within 5 half-lives of the drug).
6. Major surgical procedure, open biopsy, significant traumatic injury, radiation therapy and/or systemic anti-cancer therapy ≤28 days prior to enrollment. Patients must have recovered adequately from the toxicity and/or complications from these interventions before enrollment. Radiation therapy given with palliative intent is allowable if finalized ≥ 14 days prior to enrollment.
7. Known hypersensitivity to any of the trial drugs or its formulation components.
8. Active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids.
9. Requirement of systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medications ≤ 14 days prior to enrollment.
10. Uncontrolled diabetes or > Grade 1 laboratory test abnormalities in potassium, sodium, or calcium despite standard medical management or ≥ Grade 3 hypoalbuminemia, ≤ 14 days prior to enrollment.
11. Interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, or clinically significant acute lung diseases.
12. Any cardiovascular conditions as listed within the protocol.
13. Infection requiring systemic (oral or i.v.) antibacterial, antifungal or antiviral therapy ≤14 days prior to enrollment.
14. Patient unable to swallow and retain oral medication or has impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the oral trial treatment (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, small bowel resection).
15. Prior allogeneic stem cell transplantation or organ transplantation.
16. Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > NCI CTCAE v5.0 Grade 3 within 4 weeks prior to enrollment.
17. Non-healing wound, ulcer, or bone fracture.
18. Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before enrollment. Note: patients with prior or concurrent adequately treated, basal or squamous cell skin carcinoma or adequately treated in situ carcinomas are eligible.
19. Patient has known active HBV or HCV.
20. Patient has HIV infection, unless they meet certain criteria (listed within the protocol).
21. Persistent proteinuria of NCI CTCAE v5.0 Grade 3. Urine dipstick result of ≥ 3+ is allowed if protein excretion (estimated by urine protein/creatinine ratio on a random urine sample) is < 3.5 g/24 hours.
22. Unresolved clinically significant toxicity (per Investigator's assessment) greater than NCI CTCAE v5.0 Grade 1 attributed to any prior therapy/procedure, excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2 (according to NCI CTCAE v5.0).
23. Patient has any other concurrent severe and/or uncontrolled medical condition or personal, psychological, geographic or social circumstance, that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol and retention.
24. Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Regorafenib 90 mg + Tislelizumab 300 mg (Rego-Tisle); The trial will include 8 cohorts of patients, with each cohort considered as a single-arm; all patients enrolled will be treated with regorafenib at a dose of 90 mg orally once daily, on days 1 to 21 of a 28 cycle in combination with tislelizumab 300 mg intravenously day 1 (of a 28 day cycle).	Combination product: Regorafenib in combination with Tislelizumab; Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment	PFS-6 is defined as the proportion of patients who remained free of PFS event (disease progression or death) at 6 months from the date of enrollment.	6 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate	Defined as the proportion of patients who have a complete response (CR) or partial response (PR) based on investigator assessment.	24 Months
Disease Control Rate (DCR)	Defined as the proportion of patients who have CR, PR, or stable disease (SD) according to RECIST 1.1, as per investigator assessment.	24 Months
Duration of Response (DOR)	Defined as the time (in months) from first documentation of response (PR or CR) to progressive disease (PD) or death, based on investigator assessment or death, in patients who had best overall response of CR or PR.	24 Months
Growth Modulation Index (GMI)	Defined as as the ratio of time to progression (TTP) with the nth line (TTP(n)) of therapy to the TTP(n)(-1) with the n-1th line.	24 Months
Overall Survival (OS)	Defined as time from date of enrollment to date of death due to any cause. Median OS, OS at 6 months (OS-6) and OS at 12 months (OS-12) will be evaluated.	12 Months
Time to Prostate Specific Antigen (PSA) Progression	In metastatic castration-resistant prostate cancer (mCRPC) cohort only; defined as the time from the date of enrollment to the date of PSA progression based on Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria	24 Months
Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities	Frequency and severity of AEs and laboratory abnormalities	24 Months

Collaborators and Investigators

• Sponsor: Translational Research in Oncology
• Collaborators: Bayer; Novartis
• Investigators: Study Chair: Josep Tabernero, Medical Oncology Department, Vall d'Hebron Institute of Oncology, CIBERONC

Study record dates

Study Major Dates

• Study Start (Estimated): April 30, 2023
• Primary Completion (Estimated): April 30, 2025
• Study Completion (Estimated): April 30, 2025

Study Registration Dates

• First Submitted: October 12, 2022
• First Submitted That Met QC Criteria: October 12, 2022
• First Posted (Actual): October 17, 2022

Study Record Updates

• Last Update Posted (Actual): June 7, 2023
• Last Update Submitted That Met QC Criteria: June 5, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: MSS; Advanced solid tumors; pMMR; MKI; PD-1 inhibitors
• Additional Relevant MeSH Terms: Digestive System Diseases; Respiratory Tract Diseases; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Lung Diseases; Urogenital Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Genital Neoplasms, Male; Prostatic Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Lung Neoplasms; Adenoma; Neoplasms, Mesothelial; Pleural Neoplasms; Urogenital Diseases; Male Urogenital Diseases; Genital Diseases, Male; Genital Diseases; Neoplasms; Sarcoma; Prostatic Neoplasms; Carcinoma; Colorectal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Mesothelioma; Mesothelioma, Malignant; Antineoplastic Agents; Antineoplastic Agents, Immunological; Tislelizumab
• Other Study ID Numbers: TRIO042

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No